FierceBiotech12d
European VC firm Kurma closes first $154M of largest planned fund, eyes up to 20 biotech investments
Kurma plans to raise a total of 250 million euros ($276 million) for the fund, dubbed Biofund IV, which would make it the ...
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
The R&D Day event was held in advance of the anticipated 96-week data from the Phase 2b ORIGIN study of atacicept in IgAN, ...
Frontiers21d
Editorial: Interaction between virus and host cell: how do viruses cause cellular dysregulation?
1 Texas Biomedical Research Institute, Disease Intervention & Prevention (DIP) and Host Pathogen Interactions (HPI) Programs, San Antonio, TX, United States 2 Center of Scientific Excellence for ...
BioSpace1mon
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney ...
Finanznachrichten6mon
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney ...
eLife4y
A polyomavirus peptide binds to the capsid VP1 pore and has potent antiviral activity against BK and JC polyomaviruses
In pursuit of therapeutics for human polyomaviruses, we identified a peptide derived from the BK polyomavirus (BKV) minor structural proteins VP2/3 that is a potent inhibitor of BKV infection with no ...